Navigation Links
Metamark Genetics, Inc. Announces New Chief Scientific Officer
Date:9/16/2010

CAMBRIDGE, Mass., Sept. 16 /PRNewswire/ -- Metamark Genetics, Inc., a privately held molecular diagnostics company developing innovative personalized medicine approaches to optimize cancer care, announced today the appointment of Peter Blume-Jensen, M.D., Ph.D. as Chief Scientific Officer.

Dr. Blume-Jensen joins Metamark with over 20 years of experience in cancer research and oncology drug discovery. From 2001 to 2008 Dr. Blume-Jensen was department head at EMD Serono, Inc. and later at Merck Research Laboratories, Merck & Co, Inc. where he established integrated oncology R&D programs linking therapeutics to patient responder populations. During his tenure he advanced a number of pre-clinical drug programs into the clinic, and provided translational support for clinical programs. Since 2008 he served as Exec. Dir., External Scientific Affairs and Vice President of Daiichi Sankyo Research Institute, Daiichi Sankyo Inc., was 'Therapeutic Area Advisor' for Oncology, and helped formulate a global oncology R&D strategy. Dr. Blume-Jensen's pioneering work on oncogenic signaling, disease mouse models, and more recently efficacy-predictive biomarkers for oncology therapeutics is highly cited. Dr. Blume-Jensen obtained his M.D. from Copenhagen, Denmark, his Ph.D. from Dr. Carl-Henrik Heldin's laboratory at the Ludwig Institute for Cancer Research, Uppsala, Sweden, and conducted his Post-Doctoral studies in Dr. Tony Hunter's laboratory at the Salk Institute, La Jolla, CA.

Kenneth E. Weg, Metamark's Chairman and CEO stated, "Metamark is very fortunate to have attracted a true leader in the personalized oncology movement to shepherd Metamark's ambitious Research and Development efforts. We welcome Dr. Blume-Jensen to the expanding Metamark team."

Dr. Blume-Jensen stated, "I am very excited about the innovative, function-driven Metamark platform and the opportunity to join the Metamark team to help catapult the launch of the first MetamarkDx™ Prognostic Assays. I am looking forward to applying my expertise in personalized oncology medicine and predictive biomarkers to help transform Metamark into the leading next generation molecular diagnostics company."

Cautionary Note Regarding Forward-Looking Statements

This press release, and information contained on Metamark's website, contains forward-looking statements that involve substantial risks and uncertainties, including statements regarding Metamark's strategies and future plans, prospects and results, are forward-looking statements. The words "anticipate," "believe," "expect," "intend," "may," "plan," and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.   Metamark may not actually achieve the plans or expectations disclosed in its forward-looking statements, and you should not place undue reliance on its forward-looking statements.  


'/>"/>
SOURCE Metamark Genetics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Matching Genetics, Technology and Management Practices Critical to Meeting Strong Demand for Agricultural Crops
2. deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court
3. Interleukin Genetics, Inc. Receives Delisting Notification from NYSE Amex
4. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
5. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
6. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
7. Anesiva Announces Second Quarter 2008 Financial Results and Update
8. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
9. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
10. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
11. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2017)... ... 2017 , ... Today Aether announced that Aether and University of South Australia ... Melinda Gates Foundation grant, to pursue a 3D bioprinting research breakthrough ... the Gates Foundation, is said to be the largest transparently operated private foundation in ...
(Date:8/18/2017)... ... August 18, 2017 , ... OAI, a leading Silicon ... Microfluidics Industries, announces the new Model 800E front and backside, semi-automatic mask aligner ... mask aligners. OAI has already received and installed several orders for the ...
(Date:8/17/2017)... (PRWEB) , ... August 17, 2017 , ... ... cancer research and personalized medicine, today announced the launch of a new breast ... Missouri. The study’s goal is to evaluate the potential for early detection of ...
(Date:8/16/2017)... Phoenix, Arizona (PRWEB) , ... ... ... is proud to introduce the Fluidnatek® Electrospinning and Electrospraying ... and electrospraying equipment scales from table-top equipment for the lab to fully ...
Breaking Biology Technology:
(Date:4/11/2017)... MELBOURNE, Florida , April 11, 2017 ... "Company"), a security technology company, announces the appointment of independent ... John Bendheim to its Board of Directors, furthering the ... ... behalf of NXT-ID, we look forward to their guidance and ...
(Date:4/4/2017)... , April 4, 2017   EyeLock LLC ... announced that the United States Patent and Trademark Office ... broadly covers the linking of an iris image with ... transaction) and represents the company,s 45 th issued ... patent is very timely given the multi-modal biometric capabilities ...
(Date:3/29/2017)... 2017  higi, the health IT company that operates ... America , today announced a Series B investment ... EveryMove. The new investment and acquisition accelerates higi,s strategy ... transform population health activities through the collection and workflow ... higi collects and secures data today on behalf of ...
Breaking Biology News(10 mins):